Chemical Name:N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[2-[(2S)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide CAS Number:2383086-06-2 Molecular Formula:C₄₉H₅₉N₇O₇S Molecular Weight:890.11 g/mol Description:Sonrotoclax is an investigational, orally active, highly potent and selective small-molecule inhibitor of B-cell lymphoma 2 (BCL2). It is designed to overcome resistance associated with BCL2 mutations (e.g., G101V) and shows improved potency compared to first-generation inhibitors like venetoclax. It is currently in clinical development (Phase II/III trials) for various hematologic cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and others, often in combination with BTK inhibitors like zanubrutinib. Status:Investigational drug (not yet approved for commercial sale; safety and efficacy not fully established). Developed by BeOne Medicines (formerly BeiGene). Purity (for research/reference use):Typically ≥98% (as per research suppliers). Form:Solid (powder) for research purposes. Note:This product is for research use only, not for human consumption or therapeutic use without regulatory approval.
